Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Rate Of Breast Cancer In Italy Significantly Higher Than Previously Reported
A new analysis of the incidence of breast cancer in Italy per 100,000 women between the ages of 0 to 84 from 2000 to 2005 shows a 72 percent spike above official estimates issued by the Ministry of Health, with the sharpest uptick of +28.6 percent found in the youngest group studied (ages 25 to 44).

THT's One-hour 'Fastest' Service Aims To Reduce Undiagnosed HIV In Brighton & Hove
In a bid to reduce levels of undiagnosed HIV in Brighton & Hove, HIV and sexual health charity Terrence Higgins Trust (THT) is encouraging gay and bisexual men who may have been at risk to attend a local service offering one-hour HIV testing. One in four people who have HIV in the UK are undiagnosed, and there are now more people living with the condition than ever before.
News of the day
GPs Have Difficulty Separating Those With And Without Depression In Primary Care
A meta-analysis of more than 50,000 patients has shown that general practitioners (GPs) continue to have difficulty separating those with and without depression, with substantial numbers missed and misidentified. GPs looking for depression make more misidentifications (false positives of depression) than the number of depressions they correctly spot following an initial consultation but accuracy could improved by re-assessment of people suspected of having depression. These are the conclusions of an Article published Online First and in an upcoming edition of The Lancet, written by Dr Alex Mitchell, Dr Amol Vaze, and Dr Sanajay Rao of Leicester Partnership Trust and University of Leicester, Leicester, UK.
Oncology

Positive Outcome Reached At 16 Weeks For Avexa's ATC Phase III Trial

Avexa Limited (ASX:AVX) announced that the Data Safety Monitoring Board (DSMB) met today to review the 16 week data from Avexa"s apricitabine (ATC) Phase III clinical trial. The DSMB reviewed the data and recommended continuation of the study with the 800mg dose. Patients taking the 1200mg dose will be transitioned to the optimum 800mg dose to continue their therapy. "We are delighted with the recommendation by the DSMB for the continuation of the Phase III trial," said Dr Julian Chick, Avexa"s Chief Executive Officer. "The 800mg dose is considerably easier to formulate into fixed dose combinations, thus increasing the commercial potential for ATC. Given ATC"s excellent safety and activity profile, these results allow us to move forward with increased confidence in ATC as a treatment option for HIV patients." Avexa"s Phase III trial compares ATC to 3TC in drug-resistant HIV patients. The 16 Week component had three arms comparing doses of ATC at 800mg and 1200mg to the 3TC control arm. A minimum of 50 patients were enrolled in each arm. In all three arms, patients received either ATC or 3TC as part of an optimized background regimen. The trial will continue with two arms comparing the 800mg ATC dose to 3TC. The Phase III trial is being conducted with more than 130 sites worldwide. Patients from the earlier Phase IIb study, which used the 800mg ATC dose, have been successfully treated with ATC for up to three years. This provides further evidence of the safety, efficacy, and durability of 800mg ATC for the treatment of HIV. About apricitabine (ATC) Apricitabine (ATC) is an anti-HIV nucleoside reverse transcriptase inhibitor. ATC is Avexa"s lead program and has successfully completed the 96 week dosing of its Phase IIb clinical trial and commenced its Phase III trials worldwide in January 2008 in HIV patients with NRTI resistance. In clinical trials to date, ATC has shown the following characteristics: a unique resistance profile over 96 weeks of treatment, continued efficacy beyond two years of treatment, an excellent safety profile, and an ongoing immunological benefit. Dr Jonathan Coates, Avexa"s Chief Scientific Officer, is a former Project Leader for multiple anti-viral programs at GlaxoSmithKline and a co-inventor of anti-viral drug 3TC, one of the best selling anti-HIV drugs in history with over USD $8 billion in global sales to date. ATC targets a current unmet medical need that has earned the compound Fast Track status with the U.S. Food and Drug Administration. About the Data Safety Monitoring Board (DSMB) The Data Safety Monitoring Board (DSMB) for Avexa is a group of international experts that reviews, on a regular basis, accumulating data from ATC"s ongoing Phase 3 clinical trial. The DSMB advises Avexa regarding the continuing safety of trial subjects, as well as the continuing validity and scientific merit of the trial. Avexa Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009